Methocarbamol 750mg/5ml Oral Suspension Abbreviated Prescribing Information

Abbreviated Prescribing Information: Methocarbamol 750mg/5ml oral suspension. Consult Summary of Product Characteristics before prescribing. Presentation: white to off-white oral suspension containing 150mg of methocarbamol in 1 ml of oral suspension. Therapeutic Indications: Methocarbamol is indicated as a short-term adjunct to the symptomatic treatment of acute musculoskeletal disorders associated with painful muscle spasms in adults. Posology: The usual dose in adults is 10 ml (1500 mg) four times daily; however, a therapeutic response has been achieved with doses as low as 5 ml (750 mg) three times daily. In elderly patients, half the maximum adult dose or less may be sufficient to produce a therapeutic response. In patients with chronic hepatic disease, the elimination half‑life of methocarbamol may be prolonged and consideration should be given to increasing the dose interval. The duration of treatment depends on the symptoms induced by increased muscle tone but should not exceed 30 days. Method of Administration: For oral administration only. Paediatric population: Methocarbamol should not be used in children. Contra-indications: Hypersensitivity to methocarbamol or to any of the excipients, coma or pre-coma state, known brain damage or epilepsy and myasthenia gravis. Special Warnings and Precautions for use: Caution should be exercised in patients with renal and hepatic insufficiency. Given that methocarbamol may exhibit a general central nervous system depressant effect, patients should be advised regarding the potential combined effects with alcohol and other CNS depressants. Any warning from the MC, CHM CSM or MHRA: No. Black Triangle notice: Not applicable. Undesirable effects: Headache, fever, angioneurotic oedema, nausea, vomiting, dizziness, blurred vision, drowsiness, tremor, convulsion, restlessness, anxiety, confusion, anorexia, conjunctivitis with nasal congestion, leucopenia, hypersensitivity reactions (pruritic, skin rash, urticaria), flushing, bradycardia, hypotension, syncope, anaphylactic reaction, dyspepsia, jaundice including cholestatic jaundice, vertigo, mild muscular in coordination, amnesia, diplopia, nystagmus, insomnia, seizures, grand mal seizure and metallic taste. Refer to the SmPC for full details of adverse reactions. Legal Category: Prescription Only Medicine. Pack Size and NHS Price: 180 ml (fill volume: 150 ml) – £59. Marketing Authorisation Number: PL 00427/0311. Marketing Authorisation Holder: Rosemont Pharmaceuticals Ltd, Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK. Date of Preparation: [April 2026].